CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Incontinence - urinary, in women - Management
Can duloxetine be used during pregnancy and breastfeeding?
- Duloxetine should not be used during pregnancy or breastfeeding.
Basis for recommendation
- Data and experience with duloxetine are insufficient to recommend its use during pregnancy or breastfeeding [Schaefer et al, 2007].
- Complications consistent with serotonin-noradrenaline reuptake inhibitor (SNRI) toxicity, a possible drug discontinuation syndrome, or serotonin syndrome have been reported in neonates exposed to SNRIs in the third trimester [Micromedex, 2009].
- The manufacturer of duloxetine (Yentreve®) recommends that duloxetine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus, and that the use of duloxetine while breastfeeding is not recommended [ABPI Medicines Compendium, 2008a].
© NHS Institute for Innovation and Improvement